BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 15711431)

  • 1. Lack of effect of botulinum toxin on cortical excitability in patients with cranial dystonia.
    Allam N; Fonte-Boa PM; Tomaz CA; Brasil-Neto JP
    Clin Neuropharmacol; 2005; 28(1):1-5. PubMed ID: 15711431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shortened cortical silent period in facial muscles of patients with cranial dystonia.
    Currà A; Romaniello A; Berardelli A; Cruccu G; Manfredi M
    Neurology; 2000 Jan; 54(1):130-5. PubMed ID: 10636138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia.
    Gilio F; Currà A; Lorenzano C; Modugno N; Manfredi M; Berardelli A
    Ann Neurol; 2000 Jul; 48(1):20-6. PubMed ID: 10894212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurophysiological observations on the effects of botulinum toxin treatment in patients with dystonic blepharospasm.
    Valls-Sole J; Tolosa ES; Ribera G
    J Neurol Neurosurg Psychiatry; 1991 Apr; 54(4):310-3. PubMed ID: 1647444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unilateral injection of botulinum toxin in blepharospasm: single fiber electromyography and blink reflex study.
    Girlanda P; Quartarone A; Sinicropi S; Nicolosi C; Messina C
    Mov Disord; 1996 Jan; 11(1):27-31. PubMed ID: 8771064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormal motor cortex excitability during linguistic tasks in adductor-type spasmodic dysphonia.
    Suppa A; Marsili L; Giovannelli F; Di Stasio F; Rocchi L; Upadhyay N; Ruoppolo G; Cincotta M; Berardelli A
    Eur J Neurosci; 2015 Aug; 42(4):2051-60. PubMed ID: 26061279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of focal dystonia with botulinum toxin A].
    Sojer M; Wissel J; Müller J; Poewe W
    Wien Klin Wochenschr; 2001; 113 Suppl 4():6-10. PubMed ID: 15506045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrical activation of the orbicularis oculi muscle does not increase the effectiveness of botulinum toxin type A in patients with blepharospasm.
    Conte A; Fabbrini G; Belvisi D; Marsili L; Di Stasio F; Berardelli A
    Eur J Neurol; 2010 Mar; 17(3):449-55. PubMed ID: 19968711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracortical excitability in the hand motor representation in hand dystonia and blepharospasm.
    Sommer M; Ruge D; Tergau F; Beuche W; Altenmüller E; Paulus W
    Mov Disord; 2002 Sep; 17(5):1017-25. PubMed ID: 12360552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cortical representation of the orbicularis oculi muscle as assessed by transcranial magnetic stimulation (TMS).
    Roedel RM; Laskawi R; Markus H
    Laryngoscope; 2001 Nov; 111(11 Pt 1):2005-11. PubMed ID: 11801987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered functional connectivity in blepharospasm/orofacial dystonia.
    Jochim A; Li Y; Gora-Stahlberg G; Mantel T; Berndt M; Castrop F; Dresel C; Haslinger B
    Brain Behav; 2018 Jan; 8(1):e00894. PubMed ID: 29568690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Botulinum toxin type B in the management of dystonia non-responsive to botulinum toxin type A].
    Cardoso F
    Arq Neuropsiquiatr; 2003 Sep; 61(3A):607-10. PubMed ID: 14513166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment with botulinum toxin in blepharospasm].
    Grandas F
    Arch Neurobiol (Madr); 1991; 54(5):206-9. PubMed ID: 1804034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum toxin treatment in the facial muscles of humans: evidence of an action in untreated near muscles by peripheral local diffusion.
    Eleopra R; Tugnoli V; Caniatti L; De Grandis D
    Neurology; 1996 Apr; 46(4):1158-60. PubMed ID: 8780112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment with botulinum toxin in blepharospasm].
    Grandas F
    Arch Neurobiol (Madr); 1991; 54 Suppl 3():40-3. PubMed ID: 1810207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current status and prospects of medical therapy for dystonia].
    Osawa M
    Rinsho Shinkeigaku; 2006 Nov; 46(11):967-9. PubMed ID: 17432235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Off" painful dystonia in Parkinson's disease treated with botulinum toxin.
    Pacchetti C; Albani G; Martignoni E; Godi L; Alfonsi E; Nappi G
    Mov Disord; 1995 May; 10(3):333-6. PubMed ID: 7651452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormalities of motor cortex excitability preceding movement in patients with dystonia.
    Gilio F; Currà A; Inghilleri M; Lorenzano C; Suppa A; Manfredi M; Berardelli A
    Brain; 2003 Aug; 126(Pt 8):1745-54. PubMed ID: 12821524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The treatment of blepharospasm with botulinum toxin A].
    Költringer P; Haselwander H; Reisecker F
    Wien Klin Wochenschr; 1990 Jul; 102(14):403-7. PubMed ID: 2382447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shortened cortical silent period in facial muscles of patients with migraine.
    Curra A; Pierelli F; Coppola G; Barbanti P; Buzzi MG; Galeotti F; Serrao M; Truini A; Casali C; Pauri F; Cruccu G
    Pain; 2007 Nov; 132(1-2):124-31. PubMed ID: 17574759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.